{"DataElement":{"publicId":"2322184","version":"1","preferredName":"Trastuzumab Agent Administration Discontinued Reason","preferredDefinition":"the reason administration of trastuzumab was discontinued.","longName":"TRAS_AGT_ADM_DXD_RSN","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2322170","version":"1","preferredName":"Trastuzumab Agent Administration","preferredDefinition":"information related to trastuzumab, a humanized recombinant monoclonal antibody directed against the HER2- receptor protein, administration.","longName":"TRAST_AGT_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2322168","version":"1","preferredName":"Trastuzumab Agent","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI):An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1647:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0F852B-049E-7140-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"ONEDATA","dateModified":"2005-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320521","version":"1","preferredName":"Administration","preferredDefinition":"The act of administration.","longName":"C25409","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-053F-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0F852B-049F-7140-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2322181","version":"1","preferredName":"Trastuzumab Discontinued Reason","preferredDefinition":"the reason an trastuzumab was discontinued.","longName":"TRAST_DXD_RSN","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"5","maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD0F852B-04E4-7140-E034-0003BA3F9857","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"CAMPBELB","dateModified":"2005-08-02","deletedIndicator":"No"},{"value":"Cardiac adverse event","valueDescription":"Cardiac adverse event","ValueMeaning":{"publicId":"2575880","version":"1","preferredName":"Cardiac adverse event","longName":"2575880","preferredDefinition":"Cardiac adverse event","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F575-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"CAMPBELB","dateModified":"2005-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD5D07D0-7813-58B6-E034-0003BA3F9857","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"ONEDATA","dateModified":"2005-08-02","deletedIndicator":"No"},{"value":"Other cardiac adverse event","valueDescription":"Other cardiac adverse event","ValueMeaning":{"publicId":"2575881","version":"1","preferredName":"Other cardiac adverse event","longName":"2575881","preferredDefinition":"Other cardiac adverse event","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F576-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"CAMPBELB","dateModified":"2005-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD5D07D0-7817-58B6-E034-0003BA3F9857","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"ONEDATA","dateModified":"2005-08-02","deletedIndicator":"No"},{"value":"Non-cardiac adverse event","valueDescription":"Non-cardiac adverse event","ValueMeaning":{"publicId":"2575882","version":"1","preferredName":"Non-cardiac adverse event","longName":"2575882","preferredDefinition":"Non-cardiac adverse event","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F577-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"CAMPBELB","dateModified":"2005-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD5D07D0-781B-58B6-E034-0003BA3F9857","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"ONEDATA","dateModified":"2005-08-02","deletedIndicator":"No"},{"value":"Completed per protocol criteria","valueDescription":"Completed per protocol criteria","ValueMeaning":{"publicId":"2578063","version":"1","preferredName":"Completed per protocol criteria","longName":"2578063","preferredDefinition":"Completed per protocol criteria","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FDFC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-03-01","modifiedBy":"ALAIS","dateModified":"2006-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0DF47453-D13E-657B-E044-0003BA3F9857","beginDate":"2006-03-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-03-01","modifiedBy":"ONEDATA","dateModified":"2006-03-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008554","version":"1","preferredName":"Treatment/Off-treatment Reasons","preferredDefinition":"justification for or explanation of the administration or cessation of therapy.","longName":"TX_OTX_RSNS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2C9BE32-8BDB-649C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2322180","version":"1","preferredName":"Discontinued Reason","preferredDefinition":"Discontinued; stopped permanently or temporarily.:An explanation of the cause of some phenomenon or action.","longName":"C25484:C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0F852B-04CD-7140-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"ONEDATA","dateModified":"2005-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0F852B-04CE-7140-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"MAESKEB","dateModified":"2009-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811835","version":"1","longName":"Melanoma","context":"CTEP"},{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"},{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Reason for ending trastuzumab","type":"Preferred Question Text","description":"Reason for ending trastuzumab treatment","url":null,"context":"CTEP"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"FD5D1353-A73A-59F0-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-02","modifiedBy":"CAMPBELB","dateModified":"2008-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}